Pre-earnings options volume in Cidara Therapeutics is 3.0x normal with calls leading puts :. Implied volatility suggests the market is anticipating a move near 21.4%, or 31c, after results are released. Median move over the past eight quarters is 2.5%.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CDTX:
- Biotech Alert: Searches spiking for these stocks today
- Cidara Therapeutics reports Q4 EPS (19c), consensus (17c)
- Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Cidara Therapeutics Drops Even as FDA Approves Rezzayo
- Cidara Therapeutics and Melinta Therapeutics’ Rezzayo approved by FDA